Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 20/20 | 0.67 |
| ▸ | CCNT1 | O60563 | 17/20 | 0.67 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25858983 | 1.00 | CDK9 (0.67) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL25428535 | 0.80 | PDPK1 (0.45) | CDK9CCNT1 | |
| SCHEMBL30381702 | 0.80 | PDPK1 (0.45) | CDK9CCNT1 | |
| SCHEMBL16040035 | 0.80 | CDK9 (1.00) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL27371590 | 0.77 | CDK9 (0.63) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL16041405 | 0.74 | CCNT1 (0.75) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL30381731 | 0.74 | CCNT1 (0.65) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL16040786 | 0.74 | CCNT1 (0.65) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL16042436 | 0.73 | CCNT1 (1.00) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL16042172 | 0.72 | CCNT1 (1.00) | CDK9CCNT1CASP3CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, PYGB | CDK9 433/4885CCNT1 2305/4885CASP3 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.